Celcuity (CELC) Scheduled to Post Earnings on Thursday

Celcuity (NASDAQ:CELC) is scheduled to be releasing its earnings data after the market closes on Thursday, November 14th. Analysts expect Celcuity to post earnings of ($0.65) per share for the quarter.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same quarter last year, the business earned ($0.66) EPS. On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celcuity Price Performance

Shares of NASDAQ:CELC opened at $15.73 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 14.95 and a quick ratio of 14.95. The firm has a market capitalization of $582.48 million, a P/E ratio of -5.74 and a beta of 0.76. Celcuity has a 12 month low of $10.16 and a 12 month high of $22.19. The company’s fifty day moving average price is $15.27 and its 200 day moving average price is $16.12.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a research note on Thursday, August 15th. Leerink Partners initiated coverage on shares of Celcuity in a research note on Monday, July 22nd. They issued an “outperform” rating and a $29.00 price objective on the stock. Leerink Partnrs raised shares of Celcuity to a “strong-buy” rating in a report on Monday, July 22nd. Stifel Nicolaus boosted their price objective on shares of Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Finally, Lifesci Capital initiated coverage on shares of Celcuity in a report on Monday, August 26th. They set an “outperform” rating and a $27.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $29.17.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.